E. Small

Immunology · Journal of Clinical Oncology · 2000–2019

A researcher in the Science corpus: 19 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom E. Small trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Gabrilovich

Who trusts E. Small overall

  1. M. Cheever
  2. Celestia S. Higano

Papers from E. Small's perspective

Ordered by how strongly the researchers E. Small trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. (American Journal of Pathology)
  2. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (Cancer Research)
  3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
  4. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. (Journal of the National Cancer Institute)
  5. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer (Nature)
  6. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (New England Journal of Medicine)
  7. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (Nature)
  8. Integrative genomic profiling of human prostate cancer (Cancer Cell)
  9. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
  10. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer (Nature Genetics)

Their papers